预约演示
更新于：2026-02-27
Drospirenone/Estradiol
雌二醇屈螺酮
更新于：2026-02-27
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H54O5 |
InChIKeyQJUXBIVLOGRZSQ-OQMMLGNJSA-N |
CAS号350818-73-4 |
关联
13
项与 雌二醇屈螺酮 相关的临床试验JPRN-jRCT2071200065
Phase I/II study to investigate the pharmacokinetics, safety, and hormonal concentrations after single and multiple doses of LF111 (drospirenone) in healthy Japanese women
NCT03126773
A Prospective Multicenter Non-interventional Cohort Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia
NCT02269241
A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles
100 项与 雌二醇屈螺酮 相关的临床结果
登录后查看更多信息
100 项与 雌二醇屈螺酮 相关的转化医学
登录后查看更多信息
100 项与 雌二醇屈螺酮 相关的专利（医药）
登录后查看更多信息
24
项与 雌二醇屈螺酮 相关的文献（医药）2018-01-01Kardiologiia4区 · 医学
Structural and functional changes of blood vessels in women in early postmenopause, the possibility of correction of the revealed violations
4区 · 医学
Article
作者: Rebrov, A P ; Salov, I A ; Tolstov, S N
AIM:
To evaluate severity and pattern of structural and functional changes of vascular wall in early postmenopausal women receiving chronic treatment with a low-dose combination of 17β-estradiol (E2) 1 mg and drospirenone 2 mg (DRSP). Evaluation of structural and functional arterial remodeling might be important for assessment of cardiovascular risk in postmenopausal women.
MATERIALS AND METHODS:
The study included 162 early postmenopausal women with postmenopausal syndrome. The women were divided into two groups. The main group consisted of 84 patients receiving the postmenopausal hormonal therapy (PMHT) with E2 1 mg / DRSP 2 mg (Angeliq, Bayer) and the control group included 78 women not receiving PMHT. The follow-up duration was 5.2 years. 24‑h blood pressure monitoring with evaluation of arterial stiffness (RWTT, AIx, ASI, AASI, (dP/dt) max) was performed. Endothelium-dependent dilation of the brachial artery was measured using the reactive hyperemia test. Aortic pulse wave velocity (aPWV) and common carotid intima-media thickness (ccIMT) were measured ultrasonically.
RESULTS:
At baseline, increased aPWV was observed in 15 (21.4 %) women of the main group and 19 (24.3 %) women of the control group (р=0.4). At the end of study, increased aPWV was observed in both groups but the increase was more pronounced in the control group. Increased pulse blood pressure (PBP) was observed in 27 (32.1 %) patients of the main group and 26 (33.3 %) patients of the control group (р=0.87). At the end of study, PBP decreased from 47.2±7.2 to 45.3±6.9 mm Hg (р.
2015-06-16Zhonghua yi xue za zhi
[Clinical and metabolic effects of drospirenone-estradiol versus tibolone in postmenopausal women:a comparative study].
Article
作者: Cheng, Jiao ; Zhang, Zhenyu
OBJECTIVE:
To compare the clinical and metabolic effects of drospirenone-estradiol (Angeliq) versus tibolone (Livial) in postmenopausal women.
METHODS:
Twenty-seven postmenopausal women of group 1 took Angeliq (1 dose every two days) while another group 2 (n = 26) received tibolone (2.5 mg every two days) as hormone replacement therapy for 12 weeks. A retrospective analysis was used to evaluate the clinical efficacy, safety and risk factors of cardiovascular metabolism. The clinical data were collected before and after treatment, including personal interview, medical examination and ultrasound imaging of pelvic, breast and carotid artery.
RESULTS:
No statistically significant inter-group differences existed in age or body mass index. Before treatment, the level of E2 was (12 ± 10) ng/L, triglyceride (TG) (2.0 ± 1.1) mmol/L, lipoprotein-a (LPa) (47 ± 43) mmol/L in group 1 versus (23 ± 12) ng/L, (1.3 ± 0.7) mmol/L and (28 ± 14) mmol/L in group 2. After 12-week treatment, (30 ± 18) ng/L, (1.6 ± 1.1) mmol/L and (37 ± 36) mmol/L in group 1 versus (23 ± 9) ng/L, (1.1 ± 0.6) mmol/L and (18 ± 12) mmol/L in group 2. A greater incidence of vaginal bleeding and thicker endometrium were found in group 1.
CONCLUSION:
Angeliq can relieve menopausal symptoms. And its functions of regulating lipid metabolism and protecting cardiovascular system are better than those of Livial. However, its wider acceptability is limited by vaginal bleeding, thicker endometrium and breast pain.
2014-07-01Hospital pharmacy
New Connectors Coming for Enteral Feeding Tubes; Marqibo and Risk of Errors; Angeliq is Not a Birth Control Pill
Article
作者: Cohen, Michael R. ; Smetzer, Judy L.
These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them at your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the Institute for Safe Medication Practices (ISMP) Medication Errors Reporting Program. Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below. Errors, close calls, or hazardous conditions may be reported directly to ISMP through the ISMP Web site ( www.ismp.org ), by calling 800-FAIL-SAFE, or via e-mail at ismpinfo@ismp.org . ISMP guarantees the confidentiality and security of the information received and respects reporters' wishes as to the level of detail included in publications.
2
项与 雌二醇屈螺酮 相关的新闻（医药）2026-02-22
临床申请上市批准
2026-01-30
100 项与 雌二醇屈螺酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 更年期综合症 | 中国 | 2015-01-11 | |
| 绝经期后骨质疏松 | 中国 | 2009-09-29 | |
| 血管疾病 | 中国 | 2009-09-29 | |
| 血管舒缩症 | 美国 | 2005-09-28 | |
| 外阴和阴道萎缩 | 美国 | 2005-09-28 | |
| 避孕 | 加拿大 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,552 | 願夢窪襯鹹餘齋築觸製 = 鹽積襯鹹夢齋網鹽糧顧 遞構選夢觸窪顧鹽鏇窪 (衊獵願壓衊艱衊鹽糧鬱, 鬱鏇廠簾壓蓋蓋觸製觸 ~ 鏇製衊廠鹹糧齋齋網餘) 更多 | - | 2019-07-23 | |||
临床4期 | 24 | 繭蓋獵鑰製窪築遞顧構(獵膚積簾糧淵蓋網範醖) = 獵願顧製夢觸夢窪憲網 壓獵選網窪壓糧網觸齋 (積夢齋鑰衊醖膚膚願醖, 3.32) 更多 | - | 2013-05-03 | |||
Drospirenone (DRSP)+Estradiol (E) (E+DRSP) | 繭蓋獵鑰製窪築遞顧構(獵膚積簾糧淵蓋網範醖) = 顧憲製願簾淵艱築範顧 壓獵選網窪壓糧網觸齋 (積夢齋鑰衊醖膚膚願醖, 3.18) 更多 | ||||||
临床2期 | 92 | (0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)) | 顧齋鏇襯糧繭製鬱範衊(觸淵願鹽願簾襯鏇衊鏇) = 淵積獵衊糧築艱遞觸構 願鑰鹹鹹積選鹽廠壓選 (鬱齋網網膚醖齋壓鬱願, 1.49) 更多 | - | 2010-01-20 | ||
(2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)) | 顧齋鏇襯糧繭製鬱範衊(觸淵願鹽願簾襯鏇衊鏇) = 網鑰構簾築鬱範範製糧 願鑰鹹鹹積選鹽廠壓選 (鬱齋網網膚醖齋壓鬱願, 1.35) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用